No Data
No Data
Honey or arsenic? Frontline Biotechnology transfers its loss-making active pharmaceutical ingredient company, with Dory Pharmaceuticals taking over at a high stock price.
①Frontier Biotech is transferring the equity of its loss-making peptide active pharmaceutical ingredient production company to Doriz Pharmaceutical. In addition to paying the equity consideration, Doriz Pharmaceuticals also needs to help repay the debt of the trading symbol, totaling as high as 0.271 billion yuan. ②Affected by the sluggish sales of the core product Lincet Sodium Acetate Injection, Doriz Pharmaceuticals has experienced consecutive years of declining revenue and is expected to go from profit to loss in 2024, urgently needing to develop new products to turn the situation around.
Duol Pharmaceutical (301075.SZ) intends to acquire the equity of Shanghai Jianling to accelerate the extension layout of the active pharmaceutical ingredient industry.
Doray Pharmaceuticals (301075.SZ) announced that the company and its holding subsidiary, Chamdo Rui Le Kang Enterprise Management Co., Ltd. (...
DuoRui Pharmaceuticals (301075.SZ): The company and its holding subsidiaries have signed an equity transfer agreement.
Gelonghui October 10th | Dor Yu Medicine (301075.SZ) announced that in order to accelerate the extension layout of the active pharmaceutical ingredient industry and seek new revenue growth points for the company, on August 26, 2024, the company signed an "Investment Intention Agreement" with Frontier Biotech and Shanghai Jianling ("Target Company"), intending to invest in the Target Company through equity acquisition, aiming for a 70% stake. As of the date of this announcement, the company has already paid an investment intention fee of 10 million yuan. The company and its holding subsidiary, Chamdo Rui Le Kang Enterprise Management Co., Ltd. (hereinafter referred to as "Rui Le Kang", "Acquirer") this time.
Dorui Pharmaceuticals: 2024 Semi-Annual Report Summary
Dorui Pharmaceuticals: 2024 Semi-Annual Report
After listing, the mid-year report showed the first loss! The main revenue of Duori Pharmaceutical's main products was nearly halved, and the net income "snowballed" | Interpretation of the financial report.
①H1 Duoyi Pharmaceuticals' main product, Sodium Acetate Ringer's Injection, saw a 46.63% decrease in revenue compared to the same period. ②This is the company's first interim report with a loss since its listing. ③Despite the company's claim to accelerate the development of new products, R&D investment has actually decreased by nearly 50%.
No Data
No Data